FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

Merck upbeat on new data for MK-0524

Merck is sounding decidedly upbeat about the recent data on MK-0524, an experimental therapy for reducing flushing in patients with dyslipidemia. Flushing is an uncomfortable and common side effect associated with niacin and one of the primary reasons why patients stop taking the therapy. Dyslipidemia is a condition that disrupts the quantity of lipids in the blood. Merck is currently in Phase III with MK-0524A, a combination of MK-0524 and extended release niacin.

- here's the AFX report on the trial data 

More stories about experimental therapy   Phase III   Merck   combination  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 7 + 31?
To combat spam, please solve the math question above.